Evidence mapPaperPMID 36809503Full record

ArticleJournal of cancer research and clinical oncology2023

ePRO symptom follow-up of colorectal cancer patients receiving oxaliplatin-based adjuvant chemotherapy is feasible and enhances the quality of patient care: a prospective multicenter study.

Sanna Iivanainen, Ravi Ravichandra, Antti Jekunen, Reetta Arokoski, Santeri Mentu, Laura Lang, Jussi Ekström, Henri Virtanen, Vesa Kataja, Jussi P Koivunen

Registry-linked trialOpen access · hybridAbstract readMulticenter Study
In one paragraph

Article in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04081558 (Follow-up of Cancer Patients Receiving Chemotherapy or Targeted Therapy by Electronic Patient Reported Outcomes-tool), which is not on this map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04081558 nacompletednot on this map

Follow-up of Cancer Patients Receiving Chemotherapy or Targeted Therapy by Electronic Patient Reported Outcomes-tool

TypeinterventionalSponsorOulu University HospitalRan2018 to 2022Enrolled43ConditionsCancerArmsElectronic patient reported outcomes tool
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Sanna IivanainenDepartment of Oncology and Radiotherapy, Oulu University Hospital and MRC Oulu, P.B. 22, 90029, Oulu, Finland.
Ravi RavichandraDepartment of Oncology and Radiotherapy, Vaasa Central Hospital, Vaasa, Finland.
Antti JekunenDepartment of Oncology and Radiotherapy, Vaasa Central Hospital, Vaasa, Finland.
Reetta ArokoskiKaiku Health Oy, Helsinki, Finland.
Santeri MentuKaiku Health Oy, Helsinki, Finland.
Laura LangKaiku Health Oy, Helsinki, Finland.
Jussi EkströmKaiku Health Oy, Helsinki, Finland.
Henri VirtanenKaiku Health Oy, Helsinki, Finland.
Vesa KatajaKaiku Health Oy, Helsinki, Finland.
Jussi P KoivunenDepartment of Oncology and Radiotherapy, Oulu University Hospital and MRC Oulu, P.B. 22, 90029, Oulu, Finland. jussi.koivunen@ppshp.fi.
Oulu University Hospital · FIVaasa Central Hospital · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeElectronic (e) patient-reported outcomes (PROs) have been shown to improve the quality of life and survival in chemotherapy treated advanced cancer patients. We hypothesized that multidimensional ePRO centered approach could improve symptom management, streamline patient flow, and optimize the use of healthcare resources.

methodsIn this multicenter trial (NCT04081558), colorectal cancer (CRC) patients receiving oxaliplatin-based chemotherapy as adjuvant or in the first- or second-line setting in advanced disease were included in the prospective ePRO cohort, while a comparative retrospective cohort was collected from the same institutes. The investigated tool consisted of a weekly e-symptom questionnaire integrated to an urgency algorithm and laboratory value interface, which generated semi-automated decision support for chemotherapy cycle prescription and individualized symptom management.

resultsRecruitment to the ePRO cohort occurred 1/2019-1/2021 (n = 43). The comparator group (n = 194) consisted of patients treated in the same institutes 1-7/2017. The analysis was limited to adjuvant treated (n = 36 and n = 35). The feasibility of the ePRO follow-up was good with 98% reporting easy usage and 86% improved care, while health care personnel valued the easy use and logical workflow. In the ePRO cohort, 42% needed a phone call before planned chemotherapy cycles, while this was 100% in the retrospective cohort (p = 1.4e-8). Peripheral sensory neuropathy was detected significantly earlier with ePRO followed (p = 1e-5) but did not translate to earlier dose reduction, delays, or unplanned therapy termination compared to the retrospective cohort.

conclusionThe results suggest that the investigated approach is feasible and streamlines workflow. Earlier symptom detection may improve the quality in cancer care.

Indexed as

Colorectal NeoplasmsQuality of LifeChemotherapy, AdjuvantFollow-Up StudiesHumansOxaliplatinPatient CarePatient Reported Outcome MeasuresProspective StudiesRetrospective StudiesOxaliplatinAdjuvant therapyAdverse eventChemotherapyCIPNCRCePRO

Identifiers

PMID36809503
PMCPMC10374742
OpenAlexW4321438188

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.